Intervacc receives confirmation of a positive outcome for Strangvac, a vaccine against equine strangles, from the VMD in the UK
Stockholm, July 2, 2021 - Intervacc AB (“Intervacc”) announced today that the Veterinary Medicines Directorate (VMD) of the United Kingdom has give a positive outcome on their application for a Marketing Authorisation for Strangvac within the UK. Strangvac is a vaccine against equine strangles, a highly contagious infectious disease that affects horses globally. An approval after the positive outcome is expected after 40 days.
“We are delighted to receive this positive outcome from the VMD in the UK. Our application now enters a 30-day sign-off phase followed by a 10-day issue phase,